A Practical and Tactical Guide to

Pharma and Biotech Patent Valuation

Friday, December 05, 2003

About

DO YOU HAVE A FULL UNDERSTANDING OF HOW VALUATION METHODOLOGIES WILL BE AFFECTED BY PROPOSED LEGAL AND REGULATORY REFORMS?

The valuation of pharmaceutical and biotech patents has always been a complex task. However, proposed changes to the Hatch Waxman Act, and other related regulatory reforms promise to make the assessment of these patents even more complicated. Do you have all the information that you need to determine the true worth of your company's prized life sciences patents within the context of changing laws and regulation?

This innovative American Conference Institute publication will bring you cutting edge and practical information on valuation techniques, as well as targeted analysis and commentary on how legal and regulatory reform will affect these techniques. An outstanding faculty of financial analysts, consultants, and investment bankers, as well as counsel from the pharmaceutical and biotech industries, will walk you through the mechanics - and finer points of patent valuation and provide insights on the related reforms which are on the horizon.

Contents & Contributors

About

DO YOU HAVE A FULL UNDERSTANDING OF HOW VALUATION METHODOLOGIES WILL BE AFFECTED BY PROPOSED LEGAL AND REGULATORY REFORMS?

The valuation of pharmaceutical and biotech patents has always been a complex task. However, proposed changes to the Hatch Waxman Act, and other related regulatory reforms promise to make the assessment of these patents even more complicated. Do you have all the information that you need to determine the true worth of your company's prized life sciences patents within the context of changing laws and regulation?

This innovative American Conference Institute publication will bring you cutting edge and practical information on valuation techniques, as well as targeted analysis and commentary on how legal and regulatory reform will affect these techniques. An outstanding faculty of financial analysts, consultants, and investment bankers, as well as counsel from the pharmaceutical and biotech industries, will walk you through the mechanics - and finer points of patent valuation and provide insights on the related reforms which are on the horizon.

Contents & Contributors

VALUING PATENT-PROTECTED BIOPHARMACEUTICAL PRODUCTS: SALES ESTIMATES: THEY'RE CALLED ESTIMATES FOR A REASON
Michael Herman, Royalty Pharma

VALUING PATENT PROTECTED BIOPHARMACEUTICAL PRODUCTS
Troy Norris, L.E.K. Consulting LLC

VALUATION IN BIOPHARMACEUTICALS
Daniel J. Oh, Eli Lilly and Company
Tim Opler, Credit Suisse First Boston

TAX ISSUES AFFECTING THE VALUATION OF PHARMACEUTICAL AND BIOTECH PATENTS IN MULTI-NATIONAL COMPANIES: IT'S NOT HOW MUCH YOU EARN, IT'S HOW MUCH YOU KEEP
George G. Korenko, Ph.D., National Economic Research Associates, Inc.

PATENT VALUATION THE GENERIC PERSPECTIVE
Michael A. Davitz, M.D., J.D., Taro Pharmaceuticals

LEGISLATIVE, REGULATORY AND JUDICIAL DEVELOPMENTS AFFECTING VALUATION
James Leeds, Eli Lilly and Company



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0